| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 07/06/2005 | CN1634054A Injectio for inhibiting platelet aggregation and its preparation process |
| 07/06/2005 | CN1634019A Carbamaid peroxide freeze dried formulation for injection, its preparation method and uses |
| 07/06/2005 | CN1634014A Sodium ferulate oral disintegrating tablet and its preparation process |
| 07/06/2005 | CN1209363C Novel bicyclic amino-pyrazino ketone compound, its preparation method and medicinal composition having same |
| 07/06/2005 | CN1209358C Inhibitors of alpha L beta 2 mediated cell adhesion |
| 07/06/2005 | CN1209352C Hydrazine derivatives |
| 07/06/2005 | CN1209160C Skin-infiltrating film of Chinese traditional medicine for treating paralysis resulting from central nerve trauma and its preparation method |
| 07/06/2005 | CN1209142C Medicine for nourishing brain and thrombolysis |
| 07/06/2005 | CN1209137C Chinese herbal medicine for treating hemopathy |
| 07/06/2005 | CN1209124C Chinese-herb composition and method for preparing same |
| 07/05/2005 | US6914158 Amidino compounds useful as nitric oxide synthase inhibitors |
| 07/05/2005 | US6914125 Scramblase 2 |
| 07/05/2005 | US6914074 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer |
| 07/05/2005 | CA2160928C Compounds as pde iv and tnf inhibitors |
| 06/30/2005 | WO2005058951A1 Sugar chain-lacking hepatocyte growth factor |
| 06/30/2005 | WO2005058339A1 Composition for inhibiting thrombosis |
| 06/30/2005 | WO2005058332A2 Edestin-comprising agent for substitution of blood plasma and a method of its production |
| 06/30/2005 | WO2004002424A8 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 06/30/2005 | WO2003064629A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/30/2005 | US20050143457 Novel crystals of 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide derivative |
| 06/30/2005 | US20050143456 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 06/30/2005 | US20050143419 Guanidine and amidine derivatives as factor Xa inhibitors |
| 06/30/2005 | US20050143405 Dipeptidyl peptidase inhibitors that lower plasma glucose; treatment and prophylaxis of diabetes, non-insulin dependent diabetes; 2-amino-3aminomethyl-4-phenylpyridines |
| 06/30/2005 | US20050143399 Novel compounds |
| 06/30/2005 | US20050143368 Chemical compounds |
| 06/30/2005 | US20050143354 Association of an antithrombotic and aspirin |
| 06/30/2005 | US20050143305 sustained relese of saratin polypeptide to prevent platelet adhesion after vascular injury; thrombosis and restenosis inhibitor |
| 06/30/2005 | US20050143302 Inhibiting NF-kappa B-dependent target gene expression in a cell; fusions of a NEMO binding domain and a membrane translocation domain (third helix of antennapedia homeodomain or the HIV-1 Tat protein) |
| 06/30/2005 | US20050143283 with a chelating agent; improves the solution stability; lyophilized; antithrombotic agent |
| 06/30/2005 | US20050142659 Purified populations of stem cells |
| 06/30/2005 | US20050142639 Nucleotide sequence with vectors and administering apolipoproteins with data documents for binding lipids and cubulin for treatment of cardiovascular disorders |
| 06/30/2005 | US20050142636 Culturing yeast transformed with albumin-encoding nucleotide sequence in a fermentation medium; gene expression, separation, conditioning, adding sodium octanoate; cationic exchange chromatography, elution, ultrafiltration, sterilization, diafiltration, filling vessel |
| 06/30/2005 | US20050142617 gene related to bone density; possible use in the drug screening, treatment, and diagnosis of bone disorders such as osteoporosis |
| 06/30/2005 | US20050142604 Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210 |
| 06/30/2005 | US20050142167 Soluble highly branched glucose polymers and their method of production |
| 06/30/2005 | US20050142129 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 06/30/2005 | CA2550060A1 A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma |
| 06/30/2005 | CA2550012A1 Urea derivative, process for producing the same and use |
| 06/30/2005 | CA2549878A1 Glycosylation-deficient hepatocyte growth factor |
| 06/30/2005 | CA2549825A1 N-(4-carbamimidoyl-benzyl) -2-alkoxy-2-heterocyclyl acetamides as inhibitors of the formation of coagulation factors xa, ixa and thrombin induced by factor viia |
| 06/30/2005 | CA2549589A1 Prolinylarylacetamides |
| 06/30/2005 | CA2547590A1 Composition for inhibiting thrombosis |
| 06/30/2005 | CA2547064A1 New 5,6-dihydropyrin-2-one compounds useful as inhibitors of thrombin |
| 06/29/2005 | EP1548029A2 Peptid- and peptide mimetic derivatives having integrin inhibitor properties III |
| 06/29/2005 | EP1548024A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 06/29/2005 | EP1547626A2 Carrier with solid fibrinogen and solid thrombin |
| 06/29/2005 | EP1547597A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 06/29/2005 | EP1546141A1 Isoxazoles and their use in the treatment of ischemic diseases |
| 06/29/2005 | EP1546089A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 06/29/2005 | EP1546087A1 3-amino-2-hrydroxyalkanoic acids and their prodrugs |
| 06/29/2005 | EP1545614A2 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 06/29/2005 | EP1545555A2 Compositions and methods for treating epithelial and retinal tissue diseases |
| 06/29/2005 | EP1545538A2 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 06/29/2005 | EP1545534A1 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
| 06/29/2005 | EP1545514A1 Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors |
| 06/29/2005 | EP1545506A1 Use of angelicin and of its structural analogues for the treatment of thalassemia |
| 06/29/2005 | EP1487826A4 NEW CRYSTALLINE FORMS OF (2S)-N-5-(AMINO(IMINO)METHYL)-2-THIENYLMETHYL-1-(2R)-2-((CARBOXYMETHYL)AMINO)-3,3-DIPHENYLPROPANOYL-2-PYRROLIDINECARBOXAMIDE.nH2O |
| 06/29/2005 | EP1343786B1 Novel pyridine-substituted pyrazolopyridine derivatives |
| 06/29/2005 | EP1315727B1 7-oxo pyridopyrimidines |
| 06/29/2005 | EP1274701B1 [1,4']-bipiperidine compounds |
| 06/29/2005 | EP1239873B1 Use of fibrinolytic metalloproteinases for the therapeutic treatment of a blood clot |
| 06/29/2005 | EP1224462B1 Isoagglutinin-depleted blood compositions and methods of making same |
| 06/29/2005 | EP1172115B1 Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
| 06/29/2005 | CN1633506A Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis |
| 06/29/2005 | CN1633444A 6-11 bicyclic ketolide derivatives |
| 06/29/2005 | CN1633416A Nicotinamide derivates useful as p38 inhibitors |
| 06/29/2005 | CN1633414A Chemical compounds |
| 06/29/2005 | CN1633412A Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative |
| 06/29/2005 | CN1633309A Method of radio-labelling biomolecules |
| 06/29/2005 | CN1633292A Cotherapy with an oxazolidinone and a vitamin B |
| 06/29/2005 | CN1633288A Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k |
| 06/29/2005 | CN1633286A Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| 06/29/2005 | CN1633284A Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/29/2005 | CN1632116A Enhancement of virus-mediated DNA transfer |
| 06/29/2005 | CN1631417A Chinese medicinal formulation for treating enuresis and urinary incontinence |
| 06/29/2005 | CN1631361A Application of alpha cyclo-alanine in the process for preparing medicine to treat cerebrovascular and cardiovascular disease |
| 06/29/2005 | CN1208314C Factor VIIA inhibitor (thio) urea derivatives, their preparation and their use |
| 06/29/2005 | CN1208088C Medicinal compositions for preventing and treating hemorrhagic diseases associating with thrombopathy |
| 06/29/2005 | CN1208082C Yunan red drug tablet , its preparation method and use |
| 06/29/2005 | CN1208053C Treatment of hemoglobinopathy |
| 06/28/2005 | US6911542 Pyrazino[1′,2′:1,6]pyrido[3,4b]indole derivatives |
| 06/28/2005 | US6911457 Diabetes imaging probes |
| 06/28/2005 | US6911452 Central nervous system disorders, sleep disorders, eating disorders. sexual disorders, hypotensive agents |
| 06/28/2005 | US6911447 Non-aromatic carbocyclic rings; aromatic carbocyclic rings; non-aromatic heterocyclic rings; aromatic heterocyclic rings; compositions comprising the ligands of the invention as well as methods of treating diseases mediated through MC-3/MC-4 |
| 06/28/2005 | US6911443 Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
| 06/28/2005 | US6911439 Alpha 4 beta 1 integrin and CD49d/ CD29 (vla-4); antiinflammatory agents |
| 06/28/2005 | US6911211 Pharmaceutical and cosmetic carrier or composition for topical application |
| 06/28/2005 | CA2319554C Quinoxalinones as serine protease inhibitors such as factor xa and thrombin |
| 06/28/2005 | CA2129660C Tissue plasminogen activator glycosylation variants with improved therapeutic properties |
| 06/23/2005 | WO2005056778A1 Method of regulating the differentiation of hematopoietic stem cells or proliferating the same |
| 06/23/2005 | WO2004052366A9 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists |
| 06/23/2005 | WO2004028564A8 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 06/23/2005 | US20050137233 Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide |
| 06/23/2005 | US20050137230 Factor Xa-inhibitors; preventing thromboembolic illnesses and tumors; 2-amino-N-(2'-methylsulfonylbiphenyl-4-yl)-3-phenylpropionamide |
| 06/23/2005 | US20050137216 Heterocyclic sodium/proton exchange inhibitors and method |
| 06/23/2005 | US20050137180 Porphrins or azaporprins for photosensitizing therapy or photodetection with azaporprins for cardiovascular disorders and coordination with metals |
| 06/23/2005 | US20050136502 Treatment of disorders associated with elevated blood glucose or blood pressure |
| 06/23/2005 | US20050136045 Can be administered by continuous infusion or by single intravenous bolus injection; use in the treatment of arterial thrombosis and for treating myocardial infarction; reduced antigenicity and immunogenicity as compared to wild-type staphylokinase |
| 06/23/2005 | US20050136041 Transgenic cell comprising nucleotide sequences coding erythropoietin and/or glucagon-like peptides for use in treatment and prevention of blood and metabolic disorders; somatic and germ cell gene therapy; tissue engineering |
| 06/22/2005 | EP1544293A1 Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same |